How to compare these papers
Compare the comparator group, duration and measured endpoint. Weight change, glycemic measures and cardiovascular outcomes are different questions; a result for a combination cannot isolate either component.
This selected archive contains 53 notes in this topic. Groups describe study design, not a quality ranking or a complete systematic review. Publication year is the source paper year.
Questions to take to the original paper
- What material and experimental population were actually studied?
- What was compared, and which endpoint was measured?
- Were results neutral or conflicting, and what remains untested?
Preclinical study
- Semaglutide delivery enhancers: transport and barrier recovery
Semaglutide · 2026 · Researchers compared three absorption enhancers using intestinal cell layers, rat experiments and selected large-animal formulations.
- Tirzepatide and macrophage signaling in experimental fatty liver
Tirzepatide · 2026 · A diet-induced mouse model was combined with macrophage cultures, conditioned-medium experiments and Dectin-1 knockdown.
- Tirzepatide, PRKN and microvascular injury: an unresolved mechanism
Tirzepatide · 2026 · Diabetic mouse models and stressed human cardiac endothelial cells were examined, including partial PRKN silencing and lysosomal blockade.
- Retatrutide and memory tasks in diabetic rats: partial responses
Retatrutide · 2026 · Male rats with chemically induced diabetes underwent behavioral tasks and brain inflammatory and tissue measurements.
Clinical trial
- FLOW safety analysis: why kidney-function subgroups matter
Semaglutide · 2026 · A prespecified analysis grouped FLOW participants with diabetes and chronic kidney disease by their baseline kidney function.
- Semaglutide and decision-making: a secondary trial analysis
Semaglutide · 2026 · Seventy-two participants with major depressive disorder completed a reward-learning task before and after a randomized sixteen-week study.
- HD1916 semaglutide: reading a product-specific equivalence trial
Semaglutide · 2026 · An open-label randomized trial compared a defined chemically synthesized formulation with a reference medicine in Chinese adults with obesity without diabetes.
- Retatrutide metabolomics: exploratory biomarkers after phase 2
Retatrutide · 2026 · Fasting samples from two randomized phase 2 trials underwent exploratory lipidomic and metabolomic analyses.
- TRIUMPH-2: separating diabetes and obesity trial endpoints
Retatrutide · 2026 · A randomized placebo-controlled phase 3 study examined retatrutide in adults with both obesity and type 2 diabetes.
- Retatrutide and cardiovascular biomarkers: risk signals are not events
Retatrutide · 2026 · Investigators analyzed cardiovascular risk markers in adults from retatrutide obesity studies with and without diabetes.
- REIMAGINE 1: combination treatment in early type 2 diabetes
Cagrilintide / Semaglutide · 2026 · A blinded phase 3 study compared cagrilintide-semaglutide with placebo over forty weeks in adults inadequately controlled through diet and exercise.
- REIMAGINE 3: interpreting an add-on combination trial
Cagrilintide / Semaglutide · 2026 · Adults already receiving basal insulin were randomized to cagrilintide-semaglutide or placebo in a forty-week blinded study.
- Mazdutide in a US phase 2 trial: population and estimand
Mazdutide · 2026 · A multicenter randomized study evaluated mazdutide against placebo in US adults with obesity or overweight without diabetes.
- GLORY-2: extending mazdutide follow-up in Chinese adults
Mazdutide · 2026 · The phase 3 GLORY-2 study randomized Chinese adults with obesity to mazdutide or placebo alongside shared lifestyle support.
- Mazdutide versus dulaglutide: why the active comparator matters
Mazdutide · 2026 · A randomized phase 3 trial compared mazdutide with a specified dulaglutide regimen in adults receiving background oral diabetes medicines.
- Mazdutide monotherapy: placebo-controlled glycemic outcomes
Mazdutide · 2026 · Adults with diabetes inadequately controlled through diet and exercise were randomized to mazdutide or placebo for the controlled phase of a phase 3 trial.
- SURMOUNT-1 follow-up: diabetes progression over three years
Tirzepatide · 2025 · A longer analysis focused on participants who had both obesity and prediabetes.
- REDEFINE 2: a combination trial in type 2 diabetes
Cagrilintide / Semaglutide · 2025 · The population and comparison define what this combination trial can tell us.
- GLORY-1: moving from phase 2 to a larger mazdutide trial
Mazdutide · 2025 · A phase 3 study extended the evidence in Chinese adults with overweight or obesity.
- ESSENCE interim analysis: liver histology and long-term outcomes are different
Semaglutide · 2025 · The planned phase 3 interim report examined biopsy outcomes at 72 weeks.
- SUMMIT: reading a composite heart-failure endpoint
Tirzepatide · 2025 · The trial studied people with obesity and HFpEF, using clinical events and health-status measures.
- FLOW: kidney outcomes in diabetes and chronic kidney disease
Semaglutide · 2024 · A kidney-outcome trial illustrates the importance of eligibility criteria and composite endpoints.
- SURMOUNT-4: continuation and withdrawal are different questions
Tirzepatide · 2024 · A randomized withdrawal design examined maintenance after an initial treatment period.
- SURMOUNT-OSA: sleep-disordered breathing as a trial endpoint
Tirzepatide · 2024 · Two trials examined sleep-apnea measurements in adults with obesity.
- STEP 9: semaglutide, knee pain and the role of weight change
Semaglutide · 2024 · A trial in people with obesity and knee osteoarthritis measured both weight and pain.
- SYNERGY-NASH: interpreting phase 2 liver-biopsy outcomes
Tirzepatide · 2024 · The dose-finding study reported MASH resolution but called for larger and longer trials.
- SELECT: cardiovascular outcomes in a specific high-risk population
Semaglutide · 2023 · SELECT studied cardiovascular events, rather than weight change alone.
- STEP-HFpEF: symptoms and function in obesity-related heart failure
Semaglutide · 2023 · This study focused on symptoms, physical limitations and body weight in a defined heart-failure population.
- SURMOUNT-3: a study after successful lifestyle intervention
Tirzepatide · 2023 · Who entered the randomized phase is central to interpreting this study.
- Retatrutide: what the phase 2 obesity trial established
Retatrutide · 2023 · A triple-receptor approach was evaluated in an early controlled obesity study.
- Retatrutide in type 2 diabetes: glucose and weight endpoints
Retatrutide · 2023 · This phase 2 study examined glycemic control alongside body weight.
- Mazdutide: a phase 2 study in China
Mazdutide · 2023 · A regional phase 2 study examined a dual GLP-1 and glucagon receptor approach.
- OASIS 1: an oral formulation is not interchangeable with other semaglutide materials
Semaglutide · 2023 · The study investigated a specific oral pharmaceutical formulation in adults without diabetes.
- SURMOUNT-1: interpreting the first obesity trial
Tirzepatide · 2022 · A large randomized trial examined tirzepatide in adults with obesity or overweight without diabetes.
- STEP 5: what two years of follow-up adds
Semaglutide · 2022 · Longer follow-up examines maintenance during ongoing treatment, rather than permanence after stopping.
- STEP 8: semaglutide versus liraglutide in an active-comparator trial
Semaglutide · 2022 · The head-to-head comparison adds information that separate placebo trials cannot provide.
- STEP TEENS: population and BMI endpoints matter in adolescent research
Semaglutide · 2022 · The trial investigated adolescents under monitored clinical conditions, not adult research-vial use.
- SURPASS-5: evaluating tirzepatide as add-on to basal insulin
Tirzepatide · 2022 · The background insulin regimen distinguishes this trial from monotherapy research.
- Semaglutide in STEP 1: the trial behind the headline
Semaglutide · 2021 · A placebo-controlled obesity trial provides a starting point for reading the semaglutide evidence.
- STEP 3: why the behavioral intervention matters
Semaglutide · 2021 · Intensive behavioral support is part of the context when interpreting this weight-management study.
- SURPASS-2: reading a head-to-head diabetes trial
Tirzepatide / Semaglutide · 2021 · A head-to-head comparison needs its trial population, comparator and endpoint kept in view.
- Cagrilintide: investigating an amylin-based approach
Cagrilintide · 2021 · A phase 2 study investigated weight change and tolerability for an amylin analogue.
- Cagrilintide plus semaglutide: what an early combination study asks
Cagrilintide / Semaglutide · 2021 · Early combination studies prioritize safety and exposure before definitive efficacy questions.
- STEP 2: weight outcomes in adults who also had type 2 diabetes
Semaglutide · 2021 · The diabetes population makes this a different question from STEP 1.
- STEP 4: the run-in period changes who enters the comparison
Semaglutide · 2021 · A randomized-withdrawal design studied continued treatment after an initial response and tolerability period.
- SURPASS-1: tirzepatide monotherapy in a defined diabetes population
Tirzepatide · 2021 · This placebo-controlled trial investigated glucose control without background injectable diabetes therapy.
- SURPASS-3: comparing tirzepatide with titrated insulin degludec
Tirzepatide · 2021 · An open-label trial examined two treatment strategies on background oral therapy.
- SURPASS-4: glucose outcomes and cardiovascular safety are different questions
Tirzepatide · 2021 · The active-comparator trial enrolled adults with diabetes and increased cardiovascular risk.
- SUSTAIN-6: a cardiovascular noninferiority trial in high-risk diabetes
Semaglutide · 2016 · The safety-testing framework and composite endpoint are essential context.
Human physiology study
- Tirzepatide in a kidney-clinic cohort: association versus causation
Tirzepatide · 2026 · A nephrology clinic followed sixty-two adults with chronic kidney disease, diabetes and obesity after tirzepatide was prescribed in routine care.
- ESTATE: what a single-arm tirzepatide study can show
Tirzepatide · 2026 · The retrospective ESTATE study examined twenty-four-week changes in eighty-eight Japanese adults with type 2 diabetes in routine practice.
- Cagrilintide pharmacokinetics in renal and hepatic impairment
Cagrilintide · 2026 · Two small single-dose studies compared exposure across groups with different levels of renal or hepatic function.
Follow-up study
- After STEP 1: what happened following withdrawal?
Semaglutide · 2022 · The extension study highlights why an end-of-treatment result is not a permanent-outcome guarantee.
These are original reading notes on published studies, not product testimonials. Clinical studies used their own pharmaceutical formulations and protocols; their findings do not establish the safety, efficacy or equivalence of materials in our catalog. No personal-use or treatment guidance is provided.